Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC.

ABSTRACT:

Introduction

Brain metastases (BM) are common in patients with advanced EGFR-mutated (EGFRm+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic failure due to low plasma trough levels (C_min,SS) and consequently limited intracranial osimertinib exposure. We investigated the relation between osimertinib C_min,SS and BM development or progression.

Methods

A prospective multicenter cohort study, including patients receiving osimertinib for advanced EGFRm+ NSCLC. At osimertinib start, patients were allocated to the BM or no or unknown BM cohort and were further divided into subgroups based on osimertinib C_min,SS (low

SUBMITTER: Gulikers JL 

PROVIDER: S-EPMC10973185 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature